Agonist-specific coupling of a cloned human alpha1A-adrenoceptor to different second messenger pathways.
The agonist-specific coupling properties of the three cloned human alpha(1)-adrenoceptor subtypes have been compared, when expressed at similar levels in Chinese hamster ovary (CHO) cell lines, using noradrenaline and the (+/-)- meta- and (+/-)- para- structural isomers of octopamine as agonists. The alpha(1A)- and the alpha(1B)-adrenoceptor subtypes coupled to both the release of arachidonic acid and to the accumulation of inositol phosphates, whereas the alpha(1D)-adrenoceptor subtype only coupled effectively to the accumulation of inositol phosphates. The rank order of potencies of the three agonists tested was the same for all the three receptor subtypes when coupled to either signalling pathway: noradrenaline > meta-octopamine > para-octopamine. Meta-octopamine was a partial agonist of the alpha(1A)-adrenoceptor subtype when coupled to arachidonic acid release, whereas para-octopamine was a full agonist of this pathway. In contrast, meta-octopamine was a full agonist at the alpha(1B)-adrenoceptor subtype when coupled to arachidonic acid release, whereas para-octopamine was a partial agonist of this pathway. Neither meta-octopamine, nor para-octopamine acted as full agonists when coupling any of the three alpha(1)-adrenoceptor subtypes to the accumulation of inositol phosphates. Para-octopamine was only a weak partial agonist of this pathway for all three receptor subtypes. The results show that the modulation of arachidonic acid release and inositol 1,4,5-trisphosphate production occurs in both a subtype- and agonist-specific manner for the alpha(1A)-, alpha(1B)- and alpha(1D)-adrenoceptor subtypes. In addition, the alpha(1A)-adrenoceptor exhibits agonist-specific coupling (agonist trafficking) to the different second messenger pathways.
Richardson
Joanna
J
The Laboratory of Receptor Signalling, The Babraham Institute, Cambridge, UK.
Chatwin
Heather
H
Hirasawa
Akira
A
Tsujimoto
Gozoh
G
Evans
Peter D
PD
D000316:Adrenergic alpha-Agonists / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D016718:Arachidonic Acid / Q000096:biosynthesis; D016466:CHO Cells; D003001:Cloning, Molecular; D006224:Cricetinae; D019204:GTP-Binding Proteins / Q000378:metabolism; D006801:Humans; D007295:Inositol Phosphates / Q000096:biosynthesis; D007536:Isomerism; D015394:Molecular Structure; D009638:Norepinephrine / Q000494:pharmacology*; D009655:Octopamine / Q000737:chemistry / Q000494:pharmacology*; D011869:Radioligand Assay; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D015290:Second Messenger Systems / Q000502:physiology*
C547713:ADRA1A protein, human; C547716:ADRA1B protein, human; C547719:ADRA1D protein, human; D000316:Adrenergic alpha-Agonists; D007295:Inositol Phosphates; D018340:Receptors, Adrenergic, alpha-1; D009655:Octopamine; D016718:Arachidonic Acid; D019204:GTP-Binding Proteins; D009638:Norepinephrine